News & Updates

Show Multimedia Only

Behavioural noninferior to drug therapy for OAB symptoms in Parkinson’s disease

27 Jul 2025

In the treatment of overactive bladder (OAB) in patients with Parkinson’s disease (PD), behavioural therapy compares favourably with drug therapy, according to the results of a noninferiority study.

Behavioural noninferior to drug therapy for OAB symptoms in Parkinson’s disease

27 Jul 2025

$ABI-009 safe in children with refractory epilepsy$

ABI-009 safe in children with refractory epilepsy

25 Jul 2025

In the treatment of paediatric patients with medically and surgically refractory epilepsy, the use of ABI-009 appears safe and tolerable, with early signs of efficacy, according to data from a phase I study.

ABI-009 safe in children with refractory epilepsy

25 Jul 2025

Cenobamate cuts SUDEP risk

25 Jul 2025 by

A study presented at EAN 2025 demonstrates a reduction in the risk of sudden unexpected death in epilepsy (SUDEP) following treatment with the antiseizure medication (ASM) cenobamate among Spanish individuals in the phase III C021 study. The reductions were based on SUDEP-3 and SUDEP-7 risk scores.

Cenobamate cuts SUDEP risk

25 Jul 2025

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

24 Jul 2025 by

Individuals with tardive dyskinesia (TD) report favourable outcomes with the VMAT2 inhibitor deutetrabenazine in an age subgroup analysis.

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

24 Jul 2025

Early-onset neonatal sepsis ups risk of childhood epilepsy

23 Jul 2025

Infants who contract an invasive bacterial infection during the first week of life have double the risk of epilepsy in childhood, according to a register-based cohort study from Denmark.

Early-onset neonatal sepsis ups risk of childhood epilepsy

23 Jul 2025

GLP-1 RAs show signal of benefit in fibromyalgia

18 Jul 2025 by

New research suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity, may hold therapeutic potential for patients with fibromyalgia.

GLP-1 RAs show signal of benefit in fibromyalgia

18 Jul 2025

Is sildenafil neuroprotective?

14 Jul 2025 by

A systematic review and meta-analysis conducted by researchers from Singapore demonstrates an association between treatment with sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, and the risk of Alzheimer's disease (AD).

Is sildenafil neuroprotective?

14 Jul 2025

CGRP-targeted therapies herald a new era in migraine management

14 Jul 2025 by

Calcitonin gene–related peptide (CGRP)–targeted therapies are likely to become a mainstay of migraine headache treatment in the coming decades as they have demonstrated efficacy for acute and preventive treatment, according to Dr Yi-Jing Zhao of Mount Elizabeth Hospital, Singapore, who spoke at AIM 2025.

CGRP-targeted therapies herald a new era in migraine management

14 Jul 2025

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

11 Jul 2025

Treatment with ambroxol in patients with Parkinson’s disease dementia (PDD) is safe and well tolerated but falls short of improving cognition, according to a single-centre phase II study.

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

11 Jul 2025

Fibromyalgia linked to lower sexual desire in women

08 Jul 2025

Sexual desire is reduced in women with fibromyalgia, driven primarily by age, time since diagnosis, and depressive symptoms, according to a study.

Fibromyalgia linked to lower sexual desire in women

08 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Behavioural noninferior to drug therapy for OAB symptoms in Parkinson’s disease

Behavioural noninferior to drug therapy for OAB symptoms in Parkinson’s disease

ABI-009 safe in children with refractory epilepsy

ABI-009 safe in children with refractory epilepsy

Cenobamate cuts SUDEP risk

Cenobamate cuts SUDEP risk

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

Deutetrabenazine for tardive dyskinesia yields favourable patient-reported outcomes

Early-onset neonatal sepsis ups risk of childhood epilepsy

Early-onset neonatal sepsis ups risk of childhood epilepsy

GLP-1 RAs show signal of benefit in fibromyalgia

GLP-1 RAs show signal of benefit in fibromyalgia

Is sildenafil neuroprotective?

Is sildenafil neuroprotective?

CGRP-targeted therapies herald a new era in migraine management

CGRP-targeted therapies herald a new era in migraine management

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

Fibromyalgia linked to lower sexual desire in women

Fibromyalgia linked to lower sexual desire in women